Trial reportDiabetologia1995
Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
Trial report in Diabetologia, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 205 citations in OpenAlex.
- Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.British journal of clinical pharmacology · 2009 · on this mapTrial
- The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.Diabetologia · 2006Trial
- Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.The Journal of clinical investigation · 1998 · on this mapTrial
- GLP-1 does not not acutely affect insulin sensitivity in healthy man.Diabetologia · 1996Trial
- GLP-1 physiology and pharmacology along the gut-brain axis.The Journal of clinical investigation · 2026Review
- The effect of beinaglutide on visceral fat and body weight in obese type 2 diabetic patients.Archives of medical science : AMS · 2026Article
- Annual Prize Lecture 2024: Endogenous physiological mechanisms as basis for the treatment of obesity and type 2 diabetes.The Journal of physiology · 2024Article
- GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.Nature metabolism · 2024Review
- Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.Diabetes, obesity & metabolism · 2022Article
- Advances in therapeutic peptides targeting G protein-coupled receptors.Nature reviews. Drug discovery · 2020Review
- Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function.Comprehensive Physiology · 2020Review
- Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.Obesity surgery · 2020Article
- From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy.Frontiers in endocrinology · 2019Review
- Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2018Article
- Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1.Frontiers in endocrinology · 2018Review
- Discovery, characterization, and clinical development of the glucagon-like peptides.The Journal of clinical investigation · 2017Review
- Activation of murine pre-proglucagon-producing neurons reduces food intake and body weight.The Journal of clinical investigation · 2017Article
- Extra-pancreatic effects of incretin-based therapies.Endocrine · 2014Review
- Influence of gastric emptying on the control of postprandial glycemia: physiology and therapeutic implications.Einstein (Sao Paulo, Brazil) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous infusions of glucagon-like peptide 1 (GLP-1) [7-36 amide] are glucose-dependently insulinotropic and glucagonostatic and normalize plasma glucose concentrations in non-insulin-dependent diabetic patients. It was the aim of this study to investigate whether subcutaneous GLP-1 [7-36 amide] also has an influence on insulin and glucagon secretion, and which doses are required for significant effects. Therefore, eight healthy volunteers (24 +/- 2 years, body mass index [BMI] 21.9 +/- 2.3 kg/m2) were studied in the fasting state on five occasions in randomized order. Placebo (0.9% NaCl with 1% human serum albumin) or GLP-1 [7-36 amide] in doses of 0.15, 0.5, 1.5 or 4.5 nmol/kg body weight (volume 1 ml or, at the highest dose, 2 ml) was administered subcutaneously. An intravenous glucose bolus (0.33 g/kg body weight) was injected 30 min later. Blood was drawn for the measurement of glucose, insulin, C-peptide, GLP-1 [7-36 amide], and glucagon using specific radioimmunoassays. There were dose-related increments in GLP-1 [7-36 amide] concentrations (p < 0.0001). However, basal values were reached again after 90-120 min. Before glucose administration, insulin (p < 0.0001) and C-peptide (p < 0.0004) increased, whereas glucagon (p = 0.0018) and glucose (p < 0.0001) decreased in a dose-dependent manner. After glucose stimulation, integrated increments in insulin (p = 0.0007) and C-peptide (p = 0.02) were augmented and kG-values increased (p < 0.0001) in a dose-related fashion. The extent of reactive hypoglycaemia was related to the GLP-1 [7-36 amide] dose.(ABSTRACT TRUNCATED AT 250 WORDS)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.